title: Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
abstract: Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the valency of PCV7 by including six additional serotypes highly associated with invasive pneumococcal disease (IPD). Comparisons between PCV13 and PCV7 or the pneumococcal polysaccharide vaccine have established noninferiority of PCV13 for both safety and immunogenicity profiles for use in children and adults, respectively. At the end of 2011, PCV13 had been approved and launched in 104 countries worldwide, with 54 including the vaccine in their pediatric national immunization program. Surveillance data from early adopters of PCV13 has indicated reductions are occurring in both overall IPD and IPD caused by the six non-PCV7 serotypes; early reports of serotype replacement in carriage are also emerging. While serotype replacement for PCV7 was observed to varying degrees for both carriage and disease, the extent to which this will occur for PCV13 is yet to be determined.
authors.affiliation: Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Gladstone
authors.forename: Johanna M
authors.initials: JM
authors.lastname: Jefferies
authors.forename: Saul N
authors.initials: SN
authors.lastname: Faust
authors.forename: Stuart C
authors.initials: SC
authors.lastname: Clarke
mesh_terms: D000328:Adult; D002353:Carrier State / Q000276:immunology / Q000517:prevention & control; D002648:Child; D003362:Cost-Benefit Analysis; D005843:Geography; D014943:Global Health; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D017589:Immunization Programs / Q000639:trends*; D007115:Immunization Schedule; D011008:Pneumococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011159:Population Surveillance / Q000379:methods; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000276:immunology / Q000472:pathogenicity; D016896:Treatment Outcome; D014611:Vaccination / Q000639:trends; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
chemical_list: C538862:13-valent pneumococcal vaccine; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate